Predicting passive intestinal absorption using a single parameter

QSAR and Combinatorial Science

Volumn 22, Issue 2, 2003, Pages 247-257

  Sanghvi, Tapan ^a   Ni, Nina ^a   Mayersohn, Michael ^a   Yalkowsky, Samuel H ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DELIVERY; FORECASTING;

CHEMICAL DATA; GASTROINTESTINAL ABSORPTIONS; INTESTINAL ABSORPTION; INTESTINAL FLUID; MEASUREMENTS OF; OCTANOL-WATER PARTITION COEFFICIENT; OVERSATURATION; PASSIVE TRANSPORT; SIMPLE++; SINGLE PARAMETER;

SOLUBILITY;

ACEBUTOLOL; ACETYLSALICYLIC ACID; ACICLOVIR; ALPRENOLOL; AMFEBUTAMONE; AMILORIDE; AMOXICILLIN; ANTIBIOTIC AGENT; ATENOLOL; BENSERAZIDE; BETAXOLOL; BROMAZEPAM; BUMETANIDE; CAFFEINE; CAPTOPRIL; CARBAMAZEPINE; CEFALEXIN; CHLOROTHIAZIDE; CIMETIDINE; DEXAMETHASONE; DOXORUBICIN; ENALAPRILAT; ETOPOSIDE; FAMOTIDINE; HYDROCORTISONE; KETOPROFEN; LABETALOL; PARACETAMOL; PHENAZONE; UNINDEXED DRUG;

CONFERENCE PAPER; DRUG ABSORPTION; DRUG TRANSPORT; IN VITRO STUDY; INTESTINE ABSORPTION; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; ORAL DRUG ADMINISTRATION; PARTITION COEFFICIENT; PASSIVE TRANSPORT; PREDICTION; PRIORITY JOURNAL; VALIDATION PROCESS;

EID: 0038069296     PISSN: 1611020X     EISSN: None     Source Type: Journal    
DOI: 10.1002/qsar.200390019     Document Type: Conference Paper

References (58)

1. Dressman, J., Amidon, G., and Fleisher, D., Absorption Potential: Estimating the fraction absorbed for orally administered compounds, J. Pharm. Sci. 74.588-589 (1985).
2. Macheras, P., and Symillides, M., Toward a quantitative approach for the prediction of the fraction of dose absorbed using the absorption potential concept, Biopharm. Drug Dispos. 10.43-53 (1989).
3. Sinko, P., Leesman, G., and Amidon, G., Predicting fraction dose absorbed in humans using a macroscopic mass balance approach, Pharm. Res. 8.979-988 (1991).
4. Oh, D., Curl, R., and Amidon, G., Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model, Pharm. Res. 10.264-270 (1993).
5. Johnson, K., and Swindell, A., Guidance in the setting of drug particle size specifications to minimize variability in absorption, Pharm. Res. 13.1795-1798 (1996).
6. Sanghvi, T., Ni, N., Yalkowsky, S., A simple modified absorption potential, Pharm. Res. 18.1794-1796 (2001).
7. Balon, K., Riebesehl, B., and Muller, B., Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption, Pharm. Res. 16.882-888 (1999).
8. Harris, D. C., Quantitative Chemical Analysis, W. H. Freeman and Company, New York 2000, pp. 223-225.
9. Yalkowsky, S., and Banerjee, S., Aqueous Solubility: Methods of Estimation for Organic Compounds, Marcel Dekker, Inc., New York 1992, pp. 52.
10. Amidon, G., Lennernas, H., Shah, V., and Crison, J., A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res. 12.413-420 (1995).
11. Kansy, M., Senner, F., and Gubernator, K., Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes, J. Med. Chem. 41.1007-1010 (1998).
12. Palm, K., Stenberg, P., Luthman, K., and Artursson, P., Polar molecular surface properties predict the intestinal absorption of drugs in humans, Pharm. Res. 14.568-571 (1997).
13. Lobenberg, R., and Amidon, G., Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards, Eur. J. Pharm. Biopharm. 50.3-12 (2000).
14. Walter, E., Janich, S., Roessler, B., Hilfinger, J., and Amidon, G., HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans, J. Pharm. Sci. 85.1070-1076 (1996).
15. Wessel, M., Jurs, P., Tolan, J., and Muskal, S., Prediction of human intestinal absorption of drug compounds from molecular structure, J. Chem. Inf. Comput. Sci. 38.726-735 (1998).
16. Yalkowsky, S. (Ed.), AQUASOL dATAbASE of aqueous solubility, The University of Arizona, Tucson 1999.
17. Howard, P., and Meylan, W. (Eds.), Handbook of physical properties of organic chemicals, Lewis Publishers, New York 1997.
18. Budavari, S. (Ed.), The Merck Index, Merck & Co., Rahway 1996.
19. ClogP for Windows, Version 4, Bio Byte Corp., the QSAR specialists, Claremont, CA.
20. Jain, N., and Yalkowsky, S., Estimation of the aqueous solubility I: applications to organic nonelectrolytes, J. Pharm. Sci. 90.234-252 (2001).
21. Physicians' Desk Reference, Medical Economics Data Production Company, Montvale 1994.
22. Hardman, J., Limbird, L., Molinoff, P., Ruddon, R., and Gilman, A. (Eds.), The Pharmacological Basis of Therapeutics, McGraw-Hill, New York 1996.
23. Moffat, A. (Ed.), Clarke's Isolation and Identification of Drugs, The Pharmaceutical Press, London 1986.
24. Rowland, M., and Riegelman, S., Pharmacokinetic of acetylsalicylic acid and salicylic acid after intravenous administration in man, J. Pharm, Sci. 57.1313-1319 (1968).
25. Bodin, N-O., Borg, K., Johansson, R., Obianwu, H., and Svensson, R., Absorption, distribution and excretion of alprenolol in man, dog and rat, Acta Pharmacol. Toxicol. 35.261-269 (1974).
26. Mason, W., Winer, N., Kochak, G., Cohen, I., and Bell, R., Kinetics and absolute bioavailability of atenolol, Clin. Pharmacol. Ther. 25.408-415 (1979).
27. 3-hydrocortisone in regional enteritis and ulcerative colitis, with a note on hydrocortisone production rates, Gastroenterol. 44.257-260 (1963).
28. 1-receptor antagonist metoprolol in man, J. Pharmacokinet. Biopharm. 2.347-364 (1974).
29. Ryde, E., and Ahnfelt, N-O., The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food, Eur. J. Clin. Pharmacol. 34.481-488 (1988).
30. Bressolle, F., Bres, J., and Faure-Jeantis, A., Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans, J. Pharm. Sci. 81.26-32 (1992).
31. Holford, N., Clinical pharmacokinetics and pharmacodynamics of warfarin, Clin. Pharmacokinet. 11.483-504 (1986).
32. Drusano, G., Standiford, H., Plaisance, K., Forrest, A., Leslie, J., and Caldwell, J., Absolute oral bioavailability of ciprofloxacin, Antimicrob. Agents Chemother. 30.444-446 (1986).
33. Ochs, H., Otten, H., Greenblatt, D., and Dengler, H., Diazepam absorption - effects of age, sex, and billroth gastrectomy, Dig. Dis. Sci. 27.225-230 (1982).
34. Sjovall, J., Karlsson, A., Ogenstad, S., Sandstrom, E., and Saarimaki, M., Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus, Clin. Pharmacol. Ther. 44.65-73 (1988).
35. 15Cr-labelled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 500 as probe markers for assessment in vivo of human intestinal permeability, Clin. Sci. 71.71-80 (1986).
36. Munkholm, P., Langholz, E., Hollander, D., Thornberg, K., Orholm, M., Katz, K., and Binder, V., Intestinal permeability in patients with crohn's disease and ulcerative colitis and their first degree relatives, Gut 35.68-72 (1994).
37. Tilstone, W., Dargie, H., Dargie, E., Morgan, H., and Kennedy, A., Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure, Clin. Pharmacol. Ther. 16.322-329 (1974).
38. Greenblatt, D., Divoll, M., Soong, M., Boxenbaum, H., Harmatz, J., and Shader, R., Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam, J. Clin. Pharmacol. 28.853-859 (1988).
39. Sonne, J., Loft, S., Dossing, M., Vollmer-Larsen, A., Olesen, K., Victor, M., Andreasen, F., and Andreasen, P., Bioavailability and pharmacokinetics of oxazepam, Eur. J. Clin. Pharmacol. 35.385-389 (1988).
40. 14C-oxprenolol HCl in man, Xenobiotica 16.181-191 (1986).
41. Gugler, R., Herold, W., and Dengler, H., Pharmacokinetics of pindolol in man, Eur. J. Clin. Pharmacol. 7.17-24 (1974).
42. Bodem, G., and Chidsey, C., Pharmacokinetic studies of practolol, a beta adrenergic antagonist, in man, Clin. Pharmacol. Ther. 14.26-29 (1972).
43. Lobley, R., Burrows, P., Warwick, R., Dawson, D., and Holmes, R., Simultaneous assessment of intestinal permeability and lactose tolerance with orally administered raffinose, lactose and L-arabinose, Clin. Sci. 79.175-183 (1990).
44. Ascalone, V., Cisternino, M., Sicolo, N., and De Palo, E., Bioavailability of bromazepam in man after single administration of an oral solution, Arzneimittelforschung 34.96-98 (1984).
45. Blanchard, J., and Sawers, S., The absolute bioavailability of caffeine in man, Eur. J. Clin. Pharmacol. 24.93-98 (1983).
46. Armayor, G., and Lopez, L., Lisinopril: a new angiotensin converting enzyme inhibitor, Drug Intell. Clin. Pharm. 22.365-372 (1988).
47. Humpel, M., Nieuweboer, B., Milius, W., Hanke, H., and Wendt, H., Kinectics and biotransformation of lormetazepam, Clin. Pharmacol. Ther. 28.673-679 (1980).
48. Meier, J., Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents, Am. Heart J. 104.364-373 (1983).
49. Hellstrom, K., Rosen, A., and Swahn, A., Absorption and decomposition of potassium-35s-phenoxymethyl penicillin, Clin. Pharmacol. Ther. 16.826 (1974).
50. Golding, J., Gosden, E., and Gerrell, J., Scopolamine blood levels following buccal versus ingested tablets, J. Pharmacokinet. Biopharm. 62.521-526 (1991).
51. Gardner, M., Wilner, K., Hansen, R., Fouda, H., and McMohan, G., Single and multiple dose pharmacokinetics of tenidap sodium in healthy subjects, Br. J. Clin. Pharmacol. 39.11S-15S (1995).
52. Cruickshank, J., The clinical important of cardioselectivity and lipophilicity in beta blockers, Am. Heart J. 100.160-178 (1980).
53. Schwartz, D., and Ziegler, W., Assay and pharmacokinetics of trimethoprim in man and animals, Postgrad. Med. J. 45.S32-S37 (1969).
54. Amidon, G., Patrick S., and Fleisher, D., Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds, Pharm. Res. 5.651-654 (1988).
55. Ran, Y., Yan, H., Gang, Y., Johnson, J., and Yalkowsky, S., Estimation of aqueous solubility of organic compounds by using the General Solubility Equation (GSE), Chemosphere 48.487-509 (2002).
56. Macheras, P., Reppas, C., and Dressman, J., Biopharmaceutics of Orally Administered Drugs, Ellis Horwood Limited, Hertfordshire 1995, pp. 141-142.
57. 14C] cromoglycate in man, Biochem. J 125.27P (1971).
58. Shapiro, G. G., and König, P., Cromolyn sodium: a review, Pharmacotherapy 5.156-170 (1985).